Interventional Study
a clinical trial in which a new drug or device is used to measure a specific outcome.
VX-NEN-801
A Study of the Prevalence of Apolipoprotein L1 (APOL1) Alleles Among Individuals With Proteinuric Kidney Disease Who Are of Recent African Ancestry or Geographic Origin.
Brief Description
A Study of the Prevalence of Apolipoprotein L1 (APOL1) Alleles Among Individuals With Proteinuric Kidney Disease Who Are of Recent African Ancestry or Geographic Origin.
Site Name
North Carolina Nephrology P.A. - Cary Office
790 SE Cary Parkway, Suite 101 Cary, NC 27511
Sponsor
Vertex
Estimated enrollment
2500
Estimated end date
30 June 2025
Interventional Study
a clinical trial in which a new drug or device is used to measure a specific outcome.
VX-NEN-801
A Study of the Prevalence of Apolipoprotein L1 (APOL1) Alleles Among Individuals With Proteinuric Kidney Disease Who Are of Recent African Ancestry or Geographic Origin.
Brief Description
A Study of the Prevalence of Apolipoprotein L1 (APOL1) Alleles Among Individuals With Proteinuric Kidney Disease Who Are of Recent African Ancestry or Geographic Origin.
Trial is for people with
Chronic kidney disease not caused by diabetes, a history of proteinuria and no other identifiable cause of kidney disease.
Study Goal
This clinical research study is investigating how many individuals with chronic kidney disease (CKD) not caused by diabetes have a genetic form of the disease due to a variation in the apolipoprotein L1 (APOL1) gene.
What is involved for the Patient?
Patient will be asked to provide a blood and saliva sample on the day of visit. There will only be one (1) visit for this study. Study participants will be contacted and informed of the genetic test results when they become available.